Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener; R. Bernstein; K. Butcher; B. Campbell; G. Cloud; A. Davalos; S. Davis; J. M. Ferro; M. Grond; D. Krieger; G. Ntaios; A. Slowik; E. Touzé

doi:10.1177/1747493016669849

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener^*, R. Bernstein, K. Butcher, B. Campbell, G. Cloud, A. Davalos, S. Davis, J. M. Ferro, M. Grond, D. Krieger, G. Ntaios, A. Slowik, E. Touzé

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

Original language	English (US)
Pages (from-to)	9-12
Number of pages	4
Journal	International Journal of Stroke
Volume	12
Issue number	1
DOIs	https://doi.org/10.1177/1747493016669849
State	Published - Jan 1 2017

Keywords

Ischemic stroke
dabigatran
idarucizumab
rt-PA
thrombectomy
thrombolysis

ASJC Scopus subject areas

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1747493016669849

Cite this

Diener, H. C., Bernstein, R., Butcher, K., Campbell, B., Cloud, G., Davalos, A., Davis, S., Ferro, J. M., Grond, M., Krieger, D., Ntaios, G., Slowik, A., & Touzé, E. (2017). Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. International Journal of Stroke, 12(1), 9-12. https://doi.org/10.1177/1747493016669849

@article{06859f3ff8d449868d9f725360bb89fb,

title = "Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion",

abstract = "Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.",

keywords = "Ischemic stroke, dabigatran, idarucizumab, rt-PA, thrombectomy, thrombolysis",

author = "Diener, {H. C.} and R. Bernstein and K. Butcher and B. Campbell and G. Cloud and A. Davalos and S. Davis and Ferro, {J. M.} and M. Grond and D. Krieger and G. Ntaios and A. Slowik and E. Touz{\'e}",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} 2016 World Stroke Organization.",

year = "2017",

month = jan,

day = "1",

doi = "10.1177/1747493016669849",

language = "English (US)",

volume = "12",

pages = "9--12",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke

T2 - Expert opinion

AU - Diener, H. C.

AU - Bernstein, R.

AU - Butcher, K.

AU - Campbell, B.

AU - Cloud, G.

AU - Davalos, A.

AU - Davis, S.

AU - Ferro, J. M.

AU - Grond, M.

AU - Krieger, D.

AU - Ntaios, G.

AU - Slowik, A.

AU - Touzé, E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

AB - Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.

KW - Ischemic stroke

KW - dabigatran

KW - idarucizumab

KW - rt-PA

KW - thrombectomy

KW - thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=85007201385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007201385&partnerID=8YFLogxK

U2 - 10.1177/1747493016669849

DO - 10.1177/1747493016669849

M3 - Article

C2 - 27694315

AN - SCOPUS:85007201385

SN - 1747-4930

VL - 12

SP - 9

EP - 12

JO - International Journal of Stroke

JF - International Journal of Stroke

IS - 1

ER -

Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this